The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
A correction to this article has been published: DeLeo and Otto, J. Exp. Med. 205 (3) 739
Published online
doi:10.1084/jem.20080167
The Journal of Experimental Medicine, Vol. 205, No. 2, 271-274
The Rockefeller University Press, 0022-1007 $30.00
© DeLeo et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 1003K)
Right arrow PPT slides of all figures
Right arrow Correction (v205,p739)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeLeo, F. R.
Right arrow Articles by Otto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by DeLeo, F. R.
Right arrow Articles by Otto, M.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

COMMENTARY

 An antidote for Staphylococcus aureus pneumonia?

Frank R. DeLeo and Michael Otto

F.R. DeLeo and M. Otto are at the Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840

CORRESPONDENCE F.R.D.: fdeleo{at}niaid.nih.gov


ABSTRACT
Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of bacterial infections in the United States. Severe invasive MRSA infections, which include pneumonia, are difficult to treat because the bacteria are resistant to antibiotics. A new report now shows that immunization against {alpha}-hemolysin (Hla), a cytolytic toxin secreted by most S. aureus strains, protects mice against lethal pneumonia. This finding represents the first successful vaccine strategy for the treatment of staphylococcal pneumonia.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Vaccine protection against Staphylococcus aureus pneumonia
Juliane Bubeck Wardenburg and Olaf Schneewind
J. Exp. Med. 2008 205: 287-294. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS